Published in Blood on October 02, 2003
Intravenous erythropoietin in patients with ST-segment elevation myocardial infarction: REVEAL: a randomized controlled trial. JAMA (2011) 4.09
Administration of CD34+ cells after stroke enhances neurogenesis via angiogenesis in a mouse model. J Clin Invest (2004) 4.04
Erythropoietin deficiency decreases vascular stability in mice. J Clin Invest (2008) 2.45
Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer. Br J Cancer (2006) 1.59
Role of erythropoietin in the brain. Crit Rev Oncol Hematol (2007) 1.50
Mortality risk of darbepoetin alfa versus epoetin alfa in patients with CKD: systematic review and meta-analysis. Am J Kidney Dis (2015) 1.43
Endothelial dysfunction in diabetes: the role of reparatory mechanisms. Diabetes Care (2011) 1.37
Survival and proliferative roles of erythropoietin beyond the erythroid lineage. Expert Rev Mol Med (2008) 1.36
PDGF-BB modulates hematopoiesis and tumor angiogenesis by inducing erythropoietin production in stromal cells. Nat Med (2011) 1.33
Biologic properties of endothelial progenitor cells and their potential for cell therapy. Prog Cardiovasc Dis (2007) 1.22
Physiology and pharmacology of erythropoietin. Transfus Med Hemother (2013) 1.21
Erythropoietin blockade inhibits the induction of tumor angiogenesis and progression. PLoS One (2007) 1.19
Clinical and therapeutical implications of EPC biology in atherosclerosis. J Cell Mol Med (2006) 1.18
Relationship of erythropoietin, fetal hemoglobin, and hydroxyurea treatment to tricuspid regurgitation velocity in children with sickle cell disease. Blood (2009) 1.16
Prolyl hydroxylase inhibition during hyperoxia prevents oxygen-induced retinopathy. Proc Natl Acad Sci U S A (2008) 1.12
Endothelial progenitor cells in atherosclerosis. Front Biosci (Landmark Ed) (2012) 1.09
Erythropoietin promotes the growth of tumors lacking its receptor and decreases survival of tumor-bearing mice by enhancing angiogenesis. Neoplasia (2008) 1.08
Methylprednisolone neutralizes the beneficial effects of erythropoietin in experimental spinal cord injury. Proc Natl Acad Sci U S A (2005) 1.07
Sonic hedgehog is a critical mediator of erythropoietin-induced cardiac protection in mice. J Clin Invest (2010) 1.06
Endothelial progenitor cell dysfunction in patients with progressive chronic kidney disease. Am J Physiol Renal Physiol (2009) 1.03
The origin and in vivo significance of murine and human culture-expanded endothelial progenitor cells. Am J Pathol (2006) 1.03
The role of hypoxia in 2-butoxyethanol-induced hemangiosarcoma. Toxicol Sci (2009) 1.03
Erythropoietin-induced changes in brain gene expression reveal induction of synaptic plasticity genes in experimental stroke. Proc Natl Acad Sci U S A (2012) 1.02
Isolation and characterization of human anterior cruciate ligament-derived vascular stem cells. Stem Cells Dev (2011) 1.02
Bone marrow-CNS connections: implications in the pathogenesis of diabetic retinopathy. Prog Retin Eye Res (2012) 1.01
Design and rationale of the Reduction of Infarct Expansion and Ventricular Remodeling with Erythropoietin after Large Myocardial Infarction (REVEAL) trial. Am Heart J (2010) 1.00
Endothelial progenitor cells and cardiovascular events in patients with chronic kidney disease--a prospective follow-up study. PLoS One (2010) 0.98
Activation of endothelial nitric oxide synthase is critical for erythropoietin-induced mobilization of progenitor cells. Peptides (2008) 0.97
Pharmacological preconditioning with erythropoietin attenuates the organ injury and dysfunction induced in a rat model of hemorrhagic shock. Dis Model Mech (2012) 0.97
EPO: renoprotection beyond anemia correction. Pediatr Nephrol (2006) 0.96
Targeting stem cell niches and trafficking for cardiovascular therapy. Pharmacol Ther (2010) 0.95
Do non-hemopoietic effects of erythropoietin play a beneficial role in heart failure? Heart Fail Rev (2008) 0.95
Review article: endothelial progenitor cells in renal disease. Nephrology (Carlton) (2009) 0.94
Stem cells for the treatment of skeletal muscle injury. Clin Sports Med (2009) 0.94
Intracardiac injection of erythropoietin induces stem cell recruitment and improves cardiac functions in a rat myocardial infarction model. J Cell Mol Med (2009) 0.94
Effects of erythropoietin on angiogenesis after myocardial infarction in porcine. Heart Vessels (2011) 0.92
Erythropoietin for stroke treatment: dead or alive? Crit Care (2011) 0.90
Enhanced progenitor cell recruitment and endothelial repair after selective endothelial injury of the mouse kidney. Am J Physiol Renal Physiol (2010) 0.89
Cell-based therapies for diabetic retinopathy. Curr Diab Rep (2011) 0.88
Challenges and opportunities for stem cell therapy in patients with chronic kidney disease. Kidney Int (2016) 0.87
Recombinant human erythropoietin improves the neurofunctional recovery of rats following traumatic brain injury via an increase in circulating endothelial progenitor cells. Transl Stroke Res (2014) 0.85
The effects of low-dose nepsilon-(carboxymethyl)lysine (CML) and nepsilon-(carboxyethyl)lysine (CEL), two main glycation free adducts considered as potential uremic toxins, on endothelial progenitor cell function. Cardiovasc Diabetol (2012) 0.84
Gadolinium contrast agent-induced CD163+ ferroportin+ osteogenic cells in nephrogenic systemic fibrosis. Am J Pathol (2013) 0.83
Longer-term outcomes of darbepoetin alfa versus epoetin alfa in patients with ESRD initiating hemodialysis: a quasi-experimental cohort study. Am J Kidney Dis (2015) 0.82
Fast reduction of peripheral blood endothelial progenitor cells in healthy humans exposed to acute systemic hypoxia. J Physiol (2011) 0.82
EPC mobilization after erythropoietin treatment in acute ST-elevation myocardial infarction: the REVEAL EPC substudy. J Thromb Thrombolysis (2013) 0.81
Relationship of microparticles to progenitor cells as a measure of vascular health in a diabetic population. Cytometry B Clin Cytom (2010) 0.81
Regenerative cell therapy and pharmacotherapeutic intervention in heart failure: Part 2: Pharmacological targets, agents and intervention perspectives. Neth Heart J (2008) 0.81
Immune system in renal injury and repair: burning the candle from both ends? Pharmacol Res (2008) 0.81
Darbepoetin-alpha prevents progressive left ventricular dysfunction and remodeling in nonanemic dogs with heart failure. Am J Physiol Heart Circ Physiol (2008) 0.81
Molecular mechanisms of ischemic preconditioning in the kidney. Am J Physiol Renal Physiol (2015) 0.80
Combined intermittent hypoxia and surface muscle electrostimulation as a method to increase peripheral blood progenitor cell concentration. J Transl Med (2009) 0.80
Erythropoietin supports the survival of prostate cancer, but not growth and bone metastasis. J Cell Biochem (2013) 0.80
Mechanism by which chronic kidney disease causes cardiovascular disease and the measures to manage this phenomenon. Clin Exp Nephrol (2011) 0.80
Erythropoietin: when liability becomes asset in neurovascular repair. J Clin Invest (2008) 0.80
Mobilization of circulating endothelial progenitor cells correlates with the clinical course of hantavirus disease. J Virol (2013) 0.80
Cardiovascular effects of erythropoietin an update. Adv Pharmacol (2010) 0.79
Prognostic significance of left ventricular hypertrophy observed at dialysis initiation depends on the pre-dialysis use of erythropoiesis-stimulating agents. Clin Exp Nephrol (2012) 0.79
Association of Erythropoietin Dose and Route of Administration with Clinical Outcomes for Patients on Hemodialysis in the United States. Clin J Am Soc Nephrol (2015) 0.79
Bone marrow mesenchymal stem cells transplantation promotes the release of endogenous erythropoietin after ischemic stroke. Neural Regen Res (2015) 0.79
Short- and long-term effects of erythropoietin treatment on endothelial progenitor cell levels in patients with cardiorenal syndrome. Heart (2010) 0.78
Chronic kidney disease and erectile dysfunction. World J Nephrol (2014) 0.78
Glucose, insulin, and oxygen interplay in placental hypervascularisation in diabetes mellitus. Biomed Res Int (2014) 0.78
Darbepoetin alpha reduces oxidative stress and chronic inflammation in atherosclerotic lesions of apo E deficient mice in experimental renal failure. PLoS One (2014) 0.78
Early outgrowth pro-angiogenic cell number and function do not correlate with left ventricular structure and function in conventional hemodialysis patients: a cross-sectional study. Can J Kidney Health Dis (2015) 0.78
Enhanced brain release of erythropoietin, cytokines and NO during carotid clamping. Neurol Sci (2015) 0.77
Analysis of progenitor cell mobilization and erythropoietin plasma levels in patients with acute myocardial infarction. Exp Clin Cardiol (2005) 0.76
Low Oxygen Tension Primes Aortic Endothelial Cells to the Reparative Effect of Tissue-protective Cytokines. Mol Med (2015) 0.76
Improved in vitro cultivation of endothelial progenitor cells as basis for dermal substitutes with enhanced angiogenic capabilities. Langenbecks Arch Surg (2011) 0.76
The Local HIF-2α/EPO Pathway in the Bone Marrow is Associated with Excessive Erythrocytosis and the Increase in Bone Marrow Microvessel Density in Chronic Mountain Sickness. High Alt Med Biol (2015) 0.76
Endothelial Progenitor Cells in Diabetic Microvascular Complications: Friends or Foes? Stem Cells Int (2016) 0.76
Effects of recombinant human erythropoietin on platelet activation in acute myocardial infarction: results of a double-blind, placebo-controlled, randomized trial. Am Heart J (2009) 0.76
Bone Niches, Hematopoietic Stem Cells, and Vessel Formation. Int J Mol Sci (2017) 0.75
Circulating CD133(+)VEGFR2 (+) and CD34 (+)VEGFR2 (+) cells and arterial function in patients with beta-thalassaemia major. Ann Hematol (2011) 0.75
Endothelial progenitor cells: Exploring the pleiotropic effects of statins. World J Cardiol (2017) 0.75
Acute hemodynamic effects of erythropoietin do not mediate its cardioprotective properties. Biol Open (2012) 0.75
Functional and Biological Role of Endothelial Precursor Cells in Tumour Progression: A New Potential Therapeutic Target in Haematological Malignancies. Stem Cells Int (2015) 0.75
Autologous peripheral blood-derived mononuclear cells induced by erythropoietin improve critical ischemic limbs. Ann Vasc Dis (2012) 0.75
Erythropoietin for the treatment of subarachnoid hemorrhage: A feasible ingredient for a successful medical recipe. Mol Med (2015) 0.75
Erythropoietin Stimulates Endothelial Progenitor Cells to Induce Endothelialization in an Aneurysm Neck After Coil Embolization by Modulating Vascular Endothelial Growth Factor. Stem Cells Transl Med (2016) 0.75
Erythropoietin and a nonerythropoietic peptide analog promote aortic endothelial cell repair under hypoxic conditions: role of nitric oxide. Hypoxia (Auckl) (2016) 0.75
Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med (2011) 11.11
Catheter-based renal nerve ablation and centrally generated sympathetic activity in difficult-to-control hypertensive patients: prospective case series. Hypertension (2012) 6.70
Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens (2009) 4.87
The renal arterial resistance index and renal allograft survival. N Engl J Med (2003) 4.36
New-onset diabetes after transplantation: 2003 International consensus guidelines. Proceedings of an international expert panel meeting. Barcelona, Spain, 19 February 2003. Transplantation (2003) 3.79
Heavy metal--rely on gut feelings: novel diagnostic approach to test drug compliance in patients with lanthanum intake. Nephrol Dial Transplant (2007) 2.96
Clinical proteomics: A need to define the field and to begin to set adequate standards. Proteomics Clin Appl (2007) 2.84
Wegener's granulomatosis. Lancet (2006) 2.83
Abnormal high-density lipoprotein induces endothelial dysfunction via activation of Toll-like receptor-2. Immunity (2013) 2.74
Pathogenesis and management of hypertension after kidney transplantation. J Hypertens (2011) 2.66
SuperSAGE evidence for CD14++CD16+ monocytes as a third monocyte subset. Blood (2011) 2.66
Immunosuppressive treatment protects against angiotensin II-induced renal damage. Am J Pathol (2002) 2.50
Simvastatin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation (2005) 2.49
Carotid baroreceptor stimulation, sympathetic activity, baroreflex function, and blood pressure in hypertensive patients. Hypertension (2010) 2.38
Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study. BMJ (2012) 2.32
Circulating miR-210 predicts survival in critically ill patients with acute kidney injury. Clin J Am Soc Nephrol (2011) 2.27
AT1 receptor agonistic antibodies from preeclamptic patients stimulate NADPH oxidase. Circulation (2003) 2.15
Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetrical dimethylarginine in humans. Circulation (2003) 2.12
Stimulation of endothelial progenitor cells: a new putative therapeutic effect of angiotensin II receptor antagonists. Hypertension (2005) 2.01
Circulating endothelial cells as markers for ANCA-associated small-vessel vasculitis. Lancet (2003) 2.00
Asymmetric dimethylarginine and progression of chronic kidney disease: the mild to moderate kidney disease study. J Am Soc Nephrol (2005) 2.00
Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. Blood Press (2009) 1.98
Renal cell carcinoma in transplant recipients with acquired cystic kidney disease. Clin J Am Soc Nephrol (2007) 1.95
A European Renal Best Practice (ERBP) position statement on the Kidney Disease Improving Global Outcomes (KDIGO) clinical practice guidelines on acute kidney injury: part 1: definitions, conservative management and contrast-induced nephropathy. Nephrol Dial Transplant (2012) 1.94
Excess circulating angiopoietin-2 is a strong predictor of mortality in critically ill medical patients. Crit Care (2008) 1.94
CD14++CD16+ monocytes independently predict cardiovascular events: a cohort study of 951 patients referred for elective coronary angiography. J Am Coll Cardiol (2012) 1.92
Plasma Klotho is not related to kidney function and does not predict adverse outcome in patients with chronic kidney disease. Kidney Int (2012) 1.92
Symmetric dimethylarginine (SDMA) as endogenous marker of renal function--a meta-analysis. Nephrol Dial Transplant (2006) 1.90
Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease. Mol Cell Proteomics (2010) 1.90
ADMA increases arterial stiffness and decreases cerebral blood flow in humans. Stroke (2006) 1.88
The Hannover Dialysis Outcome study: comparison of standard versus intensified extended dialysis for treatment of patients with acute kidney injury in the intensive care unit. Nephrol Dial Transplant (2009) 1.86
Loss of podocyte aPKClambda/iota causes polarity defects and nephrotic syndrome. J Am Soc Nephrol (2009) 1.86
Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis. Ann Rheum Dis (2009) 1.86
Lung-targeted RNA interference against angiopoietin-2 ameliorates multiple organ dysfunction and death in sepsis. Crit Care Med (2014) 1.83
Nephrogenesis is induced by partial nephrectomy in the elasmobranch Leucoraja erinacea. J Am Soc Nephrol (2003) 1.83
Novel baroreflex activation therapy in resistant hypertension: results of a European multi-center feasibility study. J Am Coll Cardiol (2010) 1.82
Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation (2004) 1.81
Protocol biopsy of the stable renal transplant: a multicenter study of methods and complication rates. Transplantation (2003) 1.79
FGF-23 and future cardiovascular events in patients with chronic kidney disease before initiation of dialysis treatment. Nephrol Dial Transplant (2010) 1.78
Renal insulin resistance syndrome, adiponectin and cardiovascular events in patients with kidney disease: the mild and moderate kidney disease study. J Am Soc Nephrol (2005) 1.74
Endothelial-vasoprotective effects of high-density lipoprotein are impaired in patients with type 2 diabetes mellitus but are improved after extended-release niacin therapy. Circulation (2009) 1.73
CD14++CD16+ monocytes and cardiovascular outcome in patients with chronic kidney disease. Eur Heart J (2010) 1.73
Complement 5a receptor inhibition improves renal allograft survival. J Am Soc Nephrol (2008) 1.72
Marked increase of asymmetric dimethylarginine in patients with incipient primary chronic renal disease. J Am Soc Nephrol (2002) 1.70
Eligibility for renal denervation: experience at 11 European expert centers. Hypertension (2014) 1.68
Serum neutrophil gelatinase-associated lipocalin at inception of renal replacement therapy predicts survival in critically ill patients with acute kidney injury. Crit Care (2010) 1.65
MicroRNAs as mediators and therapeutic targets in chronic kidney disease. Nat Rev Nephrol (2011) 1.65
Rapid screening of glomerular slit diaphragm integrity in larval zebrafish. Am J Physiol Renal Physiol (2007) 1.63
Asymmetric dimethylarginine, blood pressure, and renal perfusion in elderly subjects. Circulation (2003) 1.63
Urine protein patterns can serve as diagnostic tools in patients with IgA nephropathy. Kidney Int (2005) 1.63
Recommendations for biomarker identification and qualification in clinical proteomics. Sci Transl Med (2010) 1.59
CE-MS analysis of the human urinary proteome for biomarker discovery and disease diagnostics. Proteomics Clin Appl (2008) 1.57
Impact of high glucose and transforming growth factor-β on bioenergetic profiles in podocytes. Metabolism (2012) 1.55
Efficacy and cardiovascular tolerability of extended dialysis in critically ill patients: a randomized controlled study. Am J Kidney Dis (2004) 1.55
Circulating angiopoietin-2 in essential hypertension: relation to atherosclerosis, vascular inflammation, and treatment with olmesartan/pravastatin. J Hypertens (2009) 1.54
In-center intermittent peritoneal dialysis: retrospective ten-year single-center experience with thirty consecutive patients. Perit Dial Int (2008) 1.54
Early calcification of renal allografts detected by protocol biopsies: causes and clinical implications. Am J Transplant (2005) 1.54
Angiopoietin-2 in patients requiring renal replacement therapy in the ICU: relation to acute kidney injury, multiple organ dysfunction syndrome and outcome. Intensive Care Med (2009) 1.53
Valsartan in combination with lisinopril versus the respective high dose monotherapies in hypertensive patients with microalbuminuria: the VALERIA trial. J Hypertens (2008) 1.52
The phosphatonin fibroblast growth factor 23 links calcium-phosphate metabolism with left-ventricular dysfunction and atrial fibrillation. Eur Heart J (2011) 1.51
Pharmacokinetics and total elimination of meropenem and vancomycin in intensive care unit patients undergoing extended daily dialysis. Crit Care Med (2006) 1.51
Agonistic antibodies directed at the angiotensin II, AT1 receptor in preeclampsia. J Soc Gynecol Investig (2006) 1.49
TNF-alpha--accelerated apoptosis abrogates ANCA-mediated neutrophil respiratory burst by a caspase-dependent mechanism. Kidney Int (2002) 1.48
Duration of fecal shedding of Shiga toxin-producing Escherichia coli O104:H4 in patients infected during the 2011 outbreak in Germany: a multicenter study. Clin Infect Dis (2013) 1.46
Drug Repurposing Screen Identifies Foxo1-Dependent Angiopoietin-2 Regulation in Sepsis. Crit Care Med (2015) 1.45
Time course of angiopoietin-2 release during experimental human endotoxemia and sepsis. Crit Care (2009) 1.41
Identification and validation of urinary biomarkers for differential diagnosis and evaluation of therapeutic intervention in anti-neutrophil cytoplasmic antibody-associated vasculitis. Mol Cell Proteomics (2009) 1.41
Incidence of polyomavirus-nephropathy in renal allografts: influence of modern immunosuppressive drugs. Nephrol Dial Transplant (2003) 1.40
Viral Origin, Clinical Course, and Renal Outcomes in Patients With BK Virus Infection After Living-Donor Renal Transplantation. Transplantation (2016) 1.39
A pocket guide to identify patients at risk for chronic kidney disease after liver transplantation. Transpl Int (2015) 1.39
Monocyte heterogeneity in obesity and subclinical atherosclerosis. Eur Heart J (2009) 1.38
Incidence of C4d stain in protocol biopsies from renal allografts: results from a multicenter trial. Am J Transplant (2005) 1.37
Increase of infectious complications in ABO-incompatible kidney transplant recipients--a single centre experience. Nephrol Dial Transplant (2011) 1.36
Renal resistance index and progression of renal disease. Hypertension (2002) 1.35
Endothelial progenitor cell proliferation and differentiation is regulated by erythropoietin. Kidney Int (2003) 1.33
Asymmetrical dimethylarginine in idiopathic pulmonary arterial hypertension. Arterioscler Thromb Vasc Biol (2005) 1.32